Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at 12pm ET, “Putting Science First in Rare Disease Studies”.
Swiss Biotech Day
March 19, 2024
Meet Veristat in Basel at the Swiss Biotech Day, 22-23 April 2024
German Biotech Days
March 18, 2024
Meet the Veristat team at Booth #47, April 16th and 17th in Berlin.
Webinar: Advancing Development of New Oncology Therapies: Aligning with FDA’s Project FrontRunner
March 14, 2024
Thursday, April 4 | 11am EDT | 1 hour | Hosted by: Clinical Leader
In November 2022, FDA Oncology Center of Excellence (OCE) introduced Project FrontRunner to emphasize the need for new cancer drugs to be accessible to patients with early advanced metastatic cancer in an earlier clinical setting. The aim is to provide an alternative development pathway for faster approval of new treatments that does not follow the existing paradigm in which most treatments are developed for patients who have already received multiple prior lines of therapy or have failed available treatment options. Eligible development programs should have the potential to provide clinically meaningful treatment effects and/or have better safety profiles than the current “standards of care.”
Cell & Gene Meeting on the Med 2024, an ARM Conference
March 11, 2024
Meet Veristat in Rome at the Meeting on the Med Conference 2024, 9-11 April 2024
BIO-Europe Spring 2024
March 6, 2024
Meet Veristat in Barcelona at BIO-Europe Spring 2024, 18-20 March 2024
35th Pharmacovigilance USA Conference 2024
March 6, 2024
Meet Veristat in Boston at the Pharmacovigilance USA Conference
2-3 May 2024